Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Phylogenetic clustering of surveillance drug resistance mutations in HIV-1 among patients naïve to highly active antiretroviral therapy (HAART) and those who are non-adherent to treatment
FY 2016-17
Summary
Highly active antiretroviral therapy (HAART) has helped to prolong survival for people living with human immunodeficiency virus (HIV) and hamper its progression to acquired immunodeficiency disease. HAART is a customized combination of antiretroviral drugs that decrease the viral load in patients by prohibiting HIV replication. However,the success rate of HAART is compromised by the emergence of antiretroviral drug resistant mutations in HIV-1 thatdecrease the virus' susceptibility to particular drug compounds. Known surveillance drug-resistance mutations (SDRMs) are collected in the GenBank database, which can be used to quantify the prevalence of particular mutations in clinical HIV-1 isolates. The prevalence of SDRMs inHAART-naïve patients has been evaluated separately frompatients who have stopped adhering to treatment.It is yet unclear whether there distinct clusters of SDRMs in HIV-1 positive HAART-naïve individuals and HAART patients who have stopped adhering to treatment. Thus, it is hypothesized that the prevalence of SDRMs will significantly differ between HIV-positive individuals who are HAART-naïve and HAART patients who have stopped adhering to treatment in Vancouver, Canada. Patients' sequenced HIV-1 isolates will be compared to the existing databases of HIV-1 mutations, as well as to each other, to buildphylogenetic trees based on the prevalence of SDRMs. Any significant differences would corroborate that the selective forces driving the evolution of HIV-1 differ in the presence of HAART drugs. Monitoring the emergence of drug resistance using genomic epidemiology is increasingly important to inform drug combinations and doses, develop specific diagnostic assays, and monitor the evolution of HIV.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367258
Name
McLaughlin Angela M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Phylogenetic clustering of surveillance drug resistance mutations in HIV-1 among patients naïve to highly active antiretroviral therapy (HAART) and those who are non-adherent to treatment
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acquired Immune Deficiency Syndrome (Aids); Downtown Eastside (Dtes) Vancouver; Genomic Epidemiology; Highly Active Antiretroviral Therapy (Haart); Human Immunodeficiency Virus (Hiv); Infectious Disease Transmission; Naive Patients; Phylogenetic Clustering; Surveillance Drug Resistance Mutations; Treatment Adherence
Abstract
Highly active antiretroviral therapy (HAART) has helped to prolong survival for people living with human immunodeficiency virus (HIV) and hamper its progression to acquired immunodeficiency disease. HAART is a customized combination of antiretroviral drugs that decrease the viral load in patients by prohibiting HIV replication. However,the success rate of HAART is compromised by the emergence of antiretroviral drug resistant mutations in HIV-1 thatdecrease the virus' susceptibility to particular drug compounds. Known surveillance drug-resistance mutations (SDRMs) are collected in the GenBank database, which can be used to quantify the prevalence of particular mutations in clinical HIV-1 isolates. The prevalence of SDRMs inHAART-naïve patients has been evaluated separately frompatients who have stopped adhering to treatment.It is yet unclear whether there distinct clusters of SDRMs in HIV-1 positive HAART-naïve individuals and HAART patients who have stopped adhering to treatment. Thus, it is hypothesized that the prevalence of SDRMs will significantly differ between HIV-positive individuals who are HAART-naïve and HAART patients who have stopped adhering to treatment in Vancouver, Canada. Patients' sequenced HIV-1 isolates will be compared to the existing databases of HIV-1 mutations, as well as to each other, to buildphylogenetic trees based on the prevalence of SDRMs. Any significant differences would corroborate that the selective forces driving the evolution of HIV-1 differ in the presence of HAART drugs. Monitoring the emergence of drug resistance using genomic epidemiology is increasingly important to inform drug combinations and doses, develop specific diagnostic assays, and monitor the evolution of HIV.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
McLaughlin, Angela M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~